22q11.2 deletion syndrome Market Insights and Epidemiology Forecast

1. 22q11.2 deletion syndrome Market Share Analysis, Growth Opportunities and Challenges, Treatment Algorithm, Emerging Pipeline Therapies, and Epidemiology Insights 22q11.2 deletion syndrome aka DiGeorge Syndrome (DGS) is a primary immunodeficiency, often but not always, characterized by cellular (T-cell) deficiency, characteristic facies, congenital heart disease, and hypocalcemia. The abnormal formation of certain tissues causes DGS during fetal development. Approximately 90% of patients with DGS have a small deletion in chromosome number 22 at position22q11.2. Thus another name for this syndrome is the 22q11.2 deletion syndrome. Other names include velocardiofacial syndrome and conotruncal anomaly face syndrome. Patients with DGS may have any or all of the following: Unusual facial appearance - Features may include an underdeveloped chin, eyes with heavy eyelids, ears that are rotated back, and small upper portions of their ear lobes. Heart defects - These include a variety of heart (or cardiac) defects. The defects usually involve the aorta and the part of the heart from which the aorta develops. Thymus gland abnormalities - The thymus is crucial in developing the cellular (T-cell) immune system. It is normally located in the upper area of the front of the chest behind the breastbone. DelveInsight’s “22q11.2 deletion syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the 22q11.2 deletion syndrome, historical and forecasted epidemiology as well as the 22q11.2 deletion syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some of the key facts of the 22q11.2 deletion syndrome Market Report: ● Approximately 90% of 22q11.2 deletions occur spontaneously and have not been passed on from the mother or father of the child According to a review article by Kraus et al., (2018) titled “DiGeorge syndrome: Relevance of psychiatric symptoms in undiagnosed adult patients”, the 22q11 deletion syndrome (DS), also known as DiGeorge or velocardiofacial syndrome The article by Routes et al. (2016) titled “Pulmonary Complications of Primary Immunodeficiencies”, reported that DGS is found in approximately 1 in 3000 live births Gender-based Epidemiology of 22q11.2 deletion syndrome estimates that the syndrome affects males and females equally There's currently no cure for DiGeorge syndrome. Children and adults with the condition are closely monitored to check for problems, and these can be treated as they happen if needed ● ● ● ● Request a sample for the 22q11.2 deletion syndrome Market Report 22q11.2 deletion syndrome Symptoms The symptoms of 22q11.2 deletion syndrome include – ● ● ● ● Bluish skin due to poor circulation of oxygen-rich blood Frequent Infections Underdeveloped chin Low-set ears

2. ● Groove in the upper lip Epidemiology Segmentation of 22q11.2 deletion syndrome: ● ● ● ● Prevalent Cases of 22q11.2 deletion syndrome in the 7MM [2019-2032] Age-Specific Cases of 22q11.2 deletion syndrome in the 7MM [2019–2032] Gender-Specific Cases of 22q11.2 deletion syndrome in the 7MM [2019–2032] Diagnosed and Treated Cases of 22q11.2 deletion syndrome in the 7MM [2019–2032] 22q11.2 deletion syndrome Market The dynamics of the 22q11.2 deletion syndrome market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as and others during the forecasted period 2019-2032. Learn more by requesting for sample @ 22q11.2 deletion syndrome Market Landscape 22q11.2 deletion syndrome Pipeline Therapies: ● ● ● ● NFC-1 NB-001 ZYN002 Metyrosine 22q11.2 deletion syndrome Pipeline Key Companies: ● ● ● ● Avalo Therapeutics Zynerba Pharmaceuticals Nobias Therapeutics Enzyvant Therapeutics GmBH Click here to read more about 22q11.2 deletion syndrome Market Outlook 2032 Related Reports: 22q11.2 deletion syndrome Pipeline "22q11.2 deletion syndrome Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the 22q11.2 deletion syndrome market. A detailed picture of the 22q11.2 deletion syndrome pipeline landscape is provided, which includes the disease overview and 22q11.2 deletion syndrome treatment guidelines. 22q11.2 deletion syndrome Epidemiology DelveInsight's '22q11.2 deletion syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted 22q11.2 deletion syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Diagnostic Imaging Equipment Market

3. Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases. Invasive Candidiasis Market "DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW. Sialidosis Market DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Filgrastim Biosimilar Insight DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Pain Management Devices Market Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 Latest Reports by DelveInsight Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic

4. Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market To know more about our Competitive Services, Click here: Pharma Competitive Intelligence https://www.delveinsight.com/consulting/competitive-intelligence-services